PureTech Health
500 Boylston Street
Suite 1600
Boston
Massachusetts
02116
United States
Tel: 617-482-2333
Fax: 617-482-3337
Website: http://www.puretechventures.com/
Email: info@puretechventures.com
168 articles about PureTech Health
-
PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis
4/16/2024
PureTech Health plc today announced that enrollment has been completed in the ELEVATE IPF Phase 2b clinical trial evaluating LYT-100 (deupirfenidone) in patients with idiopathic pulmonary fibrosis (IPF).
-
PureTech Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers
4/11/2024
PureTech Health plc announced that the U.S. Food and Drug Administration has granted Fast Track designation for LYT-200 in combination with anti-PD1 therapy for the treatment of recurrent/metastatic head and neck squamous cell carcinomas.
-
PureTech Proposes $100 Million Capital Return
3/19/2024
PureTech Health plc, a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, announces a proposed capital return of $100 million to its shareholders by way of a tender offer.
-
Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion
3/18/2024
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, today announced the completed acquisition of its Founded Entity, Karuna Therapeutics, Inc. ("Karuna”), by Bristol Myers Squibb (NYSE: BMY) (“BMS”), which has acquired all outstanding common stock of Karuna for $330.00 per share, for a total equity value of approximately $14 billion.
-
PureTech Receives Orphan Drug Designation for LYT-200 in Acute Myeloid Leukemia
3/13/2024
PureTech Health plc, a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, announced that the U.S. Food and Drug Administration has granted orphan drug designation to LYT-200 for the treatment of AML.
-
PureTech to Present at Two Upcoming Investor Conferences - February 27, 2024
2/27/2024
PureTech Health plc today announced that members of the management team will participate at two upcoming investor conferences.
-
PureTech Founded Entity Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx ® for Pediatric ADHD Patients in Japan
2/27/2024
PureTech Health plc, a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, noted that its Founded Entity Akili, Inc. announced that its Japanese partner Shionogi & Co. Ltd has submitted Akili’s digital therapeutic SDT-001 for marketing approval with the Ministry of Health, Labor, and Welfare.
-
PureTech to Present at 42nd Annual J.P. Morgan Healthcare Conference - Jan 03, 2024
1/3/2024
PureTech Health plc announced that Daphne Zohar, Founder and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 9:00 a.m. PST / 12:00 p.m. EST.
-
PureTech Year End Update and Outlook for 2024
12/20/2023
PureTech Health plc reports on the key progress made across its Wholly Owned Programs2 and Founded Entities3 in 2023, announces two new Founded Entities and provides an update on cash and operational runway guidance.
-
PureTech Presents Data from Phase 1 Trial of LYT-200 Targeting Galectin-9 in Solid Tumors at the ESMO Immuno-Oncology Congress 2023
12/7/2023
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced a poster presentation with results from the Phase 1 portion of the Phase 1/2 dose escalation and expansion clinical trial of LYT-200 at the ESMO Immuno-Oncology Congress 2023.
-
PureTech Founded Entity Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia
11/17/2023
PureTech Health plc, a clinical-stage biotherapeutics company, noted that its Founded Entity, Karuna Therapeutics, announced positive results from its Phase 1b open-label, eight-week inpatient trial evaluating the effect of KarXT on 24-hour ambulatory blood pressure in adults with schizophrenia demonstrating that KarXT was not associated with increases in blood pressure.
-
PureTech's LYT-300 (Oral Allopregnanolone) Achieved Primary Endpoint in a Phase 2a Acute Anxiety Trial in Healthy Volunteers
11/14/2023
PureTech Health plc, a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, announced topline results from its Phase 2a, randomized, placebo-controlled, proof-of-concept trial of LYT-300.
-
PureTech Presents Data from LYT-100 (Deupirfenidone) Trial in Healthy Older Adults at CHEST Annual Meeting
10/11/2023
PureTech Health plc, a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, presented clinical data supporting the differentiated profile of LYT-100 at the CHEST Annual Meeting in Honolulu, Hawaii.
-
PureTech Founded Entity Vedanta Biosciences Announces First Patient Dosed in Phase 2 Clinical Trial of VE202 for the Treatment of Ulcerative Colitis and Receives Fast Track Designation
10/4/2023
PureTech Health plc noted today that its Founded Entity, Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, announced that the first patient in the Phase 2 COLLECTiVE202 clinical study of VE202 was dosed.
-
KarXT, invented at PureTech, submitted for FDA Approval in Schizophrenia
9/28/2023
PureTech Health plc, a clinical-stage biotherapeutics company, noted that its Founded Entity, Karuna Therapeutics, Inc. announced the submission of a New Drug Application to the U.S. Food and Drug Administration for KarXT for the treatment of schizophrenia.
-
PureTech Announces the Appointment of Robert Lyne as Chief Portfolio Officer
9/27/2023
PureTech Health plc, a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, announced the appointment of Robert Lyne as Chief Portfolio Officer.
-
PureTech Health plc – 2023 Half-Year Report
8/29/2023
PureTech Health plc announces its half-yearly results for the six months ended June 30, 2023.
-
PureTech Health: Notice of Half-Yearly Results
8/22/2023
PureTech Health plc plans to announce its half-yearly results for the six months ended June 30, 2023, on Tuesday, August 29, 2023.
-
PureTech Awarded up to $11.4 Million from U.S. Department of Defense to Advance LYT-300 (Oral Allopregnanolone) for Fragile X-associated Tremor/Ataxia Syndrome
8/1/2023
PureTech Health plc today announced that the company has been awarded up to $11.4 million from the U.S. Department of Defense (DoD) to advance its therapeutic candidate, LYT-300 (oral allopregnanolone), for the treatment of Fragile X-associated Tremor Ataxia Syndrome (FXTAS).
-
PureTech Initiates Phase 2a Clinical Trial of LYT-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders
6/21/2023
PureTech Health plc today announced the initiation of a Phase 2a proof-of-concept clinical trial of LYT-300 (oral allopregnanolone) in healthy volunteers using a validated clinical model of anxiety.